Actions of Escordi Cor in details
Calcium-channel blocker.
Pharmacology: Pharmacodynamics: S(-) Escordi Cor, the chirally pure form of Escordi Cor, is a calcium channel antagonist belonging to the dihydropyridine class. The S(-) isomer of Escordi Cor is found to possess greater pharmacological effects than R(+) Escordi Cor. S(-) Escordi Cor is 1000 times more potent than the R(+) isomer in binding to the dihydropyridine receptor. In humans, the dominant effects of Escordi Cor are consequent to vasodilation. S(-) Escordi Cor lowers peripheral vascular resistance without causing a reflex tachycardia. It is effective as a once-daily dosing in the control of hypertension.
Pharmacokinetics: Administration of S(-) Escordi Cor 2.5 mg as a single dose in the fasting state produced maximum plasma concentration (Cmax) of 8.3 ± 1.071 ng/mL in 2.73 ± 0.88 hrs (Tmax). Escordi Cor is extensively (about 90%) converted to inactive metabolites via hepatic metabolism with 10% of the parent compound and 60% of the metabolites excreted in the urine. Ex vivo studies have shown that approximately 93% of the circulating drug is bound to plasma proteins in hypertensive patients. The mean AUC0-t value (t=48 hrs) of Escordi Cor 2.5 mg is 95.33 ± 14.45 ng·hr/mL. The AUC0-∞ value is recorded to be 140.91 ± 28.06 ng·hr/mL. The plasma elimination half-life of S(-) Escordi Cor has been found to be in the range of 14.62-68.88 hrs.
How should I take Escordi Cor?
Take Escordi Cor exactly as prescribed by your doctor. Follow all directions on your prescription label. Your doctor may occasionally change your dose to make sure you get the best results. Do not use this medicine in larger or smaller amounts or for longer than recommended.
You may take Escordi Cor with or without food. Take the medicine at the same time each day.
Your blood pressure will need to be checked often.
Your chest pain may become worse when you first start taking Escordi Cor or when your dose is increased. Call your doctor if your chest pain is severe or ongoing.
If you are being treated for high blood pressure, keep using Escordi Cor even if you feel well. High blood pressure often has no symptoms. You may need to use blood pressure medicine for the rest of your life.
Your hypertension or heart condition may be treated with a combination of drugs. Use all medications as directed by your doctor. Read the medication guide or patient instructions provided with each medication. Do not change your doses or stop taking any of your medications without your doctor's advice. This is especially important if you also take nitroglycerin.
Escordi Cor is only part of a complete program of treatment that may also include diet, exercise, weight control, and other medications. Follow your diet, medication, and exercise routines very closely.
Store at room temperature away from moisture, heat, and light.
Escordi Cor administration
Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.
Escordi Cor is usually taken once daily. Your doctor may occasionally change your dose to make sure you get the best results.
Your chest pain may become worse when you first start taking Escordi Cor or when your dose is increased. Call your doctor if your chest pain is severe or ongoing.
Escordi Cor is only part of a complete program of treatment that may also include diet, exercise, weight control, and other medications. Follow your diet, medication, and exercise routines very closely.
If you are being treated for high blood pressure, keep using this medication even if you feel well. High blood pressure often has no symptoms. You may need to use blood pressure medication for the rest of your life.
Store at room temperature away from moisture, heat, and light.
Escordi Cor pharmacology
Mechanism of Action
Escordi Cor is a dihydropyridine calcium antagonist (calcium ion antagonist or slow-channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that Escordi Cor binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. Escordi Cor inhibits calcium ion influx across cell membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells. Negative inotropic effects can be detected in vitro but such effects have not been seen in intact animals at therapeutic doses. Serum calcium concentration is not affected by Escordi Cor. Within the physiologic pH range, Escordi Cor is an ionized compound (pKa=8.6), and its kinetic interaction with the calcium channel receptor is characterized by a gradual rate of association and dissociation with the receptor binding site, resulting in a gradual onset of effect.
Escordi Cor is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure.
The precise mechanisms by which Escordi Cor relieves angina have not been fully delineated, but are thought to include the following:
Exertional Angina: In patients with exertional angina, Escordi Cor reduces the total peripheral resistance (afterload) against which the heart works and reduces the rate pressure product, and thus myocardial oxygen demand, at any given level of exercise.
Vasospastic Angina: Escordi Cor has been demonstrated to block constriction and restore blood flow in coronary arteries and arterioles in response to calcium, potassium epinephrine, serotonin, and thromboxane A2 analog in experimental animal models and in human coronary vessels in vitro. This inhibition of coronary spasm is responsible for the effectiveness of Escordi Cor in vasospastic (Prinzmetal's or variant) angina.
Pharmacodynamics
Hemodynamics: Following administration of therapeutic doses to patients with hypertension, Escordi Cor produces vasodilation resulting in a reduction of supine and standing blood pressures. These decreases in blood pressure are not accompanied by a significant change in heart rate or plasma catecholamine levels with chronic dosing. Although the acute intravenous administration of Escordi Cor decreases arterial blood pressure and increases heart rate in hemodynamic studies of patients with chronic stable angina, chronic oral administration of Escordi Cor in clinical trials did not lead to clinically significant changes in heart rate or blood pressures in normotensive patients with angina.
With chronic once daily oral administration, antihypertensive effectiveness is maintained for at least 24 hours. Plasma concentrations correlate with effect in both young and elderly patients. The magnitude of reduction in blood pressure with Escordi Cor is also correlated with the height of pretreatment elevation; thus, individuals with moderate hypertension (diastolic pressure 105–114 mmHg) had about a 50% greater response than patients with mild hypertension (diastolic pressure 90–104 mmHg). Normotensive subjects experienced no clinically significant change in blood pressures (+1/–2 mmHg).
In hypertensive patients with normal renal function, therapeutic doses of Escordi Cor resulted in a decrease in renal vascular resistance and an increase in glomerular filtration rate and effective renal plasma flow without change in filtration fraction or proteinuria.
As with other calcium channel blockers, hemodynamic measurements of cardiac function at rest and during exercise (or pacing) in patients with normal ventricular function treated with Escordi Cor have generally demonstrated a small increase in cardiac index without significant influence on dP/dt or on left ventricular end diastolic pressure or volume. In hemodynamic studies, Escordi Cor has not been associated with a negative inotropic effect when administered in the therapeutic dose range to intact animals and man, even when co-administered with beta-blockers to man. Similar findings, however, have been observed in normal or well-compensated patients with heart failure with agents possessing significant negative inotropic effects.
Electrophysiologic Effects: Escordi Cor does not change sinoatrial nodal function or atrioventricular conduction in intact animals or man. In patients with chronic stable angina, intravenous administration of 10 mg did not significantly alter A-H and H-V conduction and sinus node recovery time after pacing. Similar results were obtained in patients receiving Escordi Cor and concomitant beta-blockers. In clinical studies in which Escordi Cor was administered in combination with beta-blockers to patients with either hypertension or angina, no adverse effects on electrocardiographic parameters were observed. In clinical trials with angina patients alone, Escordi Cor therapy did not alter electrocardiographic intervals or produce higher degrees of AV blocks.
Drug interactions
Sildenafil: When Escordi Cor and sildenafil were used in combination, each agent independently exerted its own blood pressure lowering effect.
Pharmacokinetics
After oral administration of therapeutic doses of Escordi Cor, absorption produces peak plasma concentrations between 6 and 12 hours. Absolute bioavailability has been estimated to be between 64 and 90%. The bioavailability of Escordi Cor is not altered by the presence of food.
Escordi Cor is extensively (about 90%) converted to inactive metabolites via hepatic metabolism with 10% of the parent compound and 60% of the metabolites excreted in the urine. Ex vivo studies have shown that approximately 93% of the circulating drug is bound to plasma proteins in hypertensive patients. Elimination from the plasma is biphasic with a terminal elimination half-life of about 30–50 hours. Steady-state plasma levels of Escordi Cor are reached after 7 to 8 days of consecutive daily dosing.
The pharmacokinetics of Escordi Cor are not significantly influenced by renal impairment. Patients with renal failure may therefore receive the usual initial dose.
Elderly patients and patients with hepatic insufficiency have decreased clearance of Escordi Cor with a resulting increase in AUC of approximately 40–60%, and a lower initial dose may be required. A similar increase in AUC was observed in patients with moderate to severe heart failure.
Drug interactions
In vitro data indicate that Escordi Cor has no effect on the human plasma protein binding of digoxin, phenytoin, warfarin, and indomethacin.
Impact of other drugs on Escordi Cor
Co-administered cimetidine, magnesium-and aluminum hydroxide antacids, sildenafil, and grapefruit juice have no impact on the exposure to Escordi Cor.
CYP3A inhibitors: Co-administration of a 180 mg daily dose of diltiazem with 5 mg Escordi Cor in elderly hypertensive patients resulted in a 60% increase in Escordi Cor systemic exposure. Erythromycin co-administration in healthy volunteers did not significantly change Escordi Cor systemic exposure. However, strong inhibitors of CYP3A (e.g., itraconazole, clarithromycin) may increase the plasma concentrations of Escordi Cor to a greater extent.
Impact of Escordi Cor on other drugs
Co-administered Escordi Cor does not affect the exposure to atorvastatin, digoxin, ethanol and the warfarin prothrombin response time.
Simvastatin: Co-administration of multiple doses of 10 mg of Escordi Cor with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone.
Cyclosporine: A prospective study in renal transplant patients (N=11) showed on an average of 40% increase in trough cyclosporine levels when concomitantly treated with Escordi Cor.
Tacrolimus: A prospective study in healthy Chinese volunteers (N=9) with CYP3A5 expressers showed a 2.5- to 4-fold increase in tacrolimus exposure when concomitantly administered with Escordi Cor compared to tacrolimus alone. This finding was not observed in CYP3A5 non-expressers (N= 6). However, a 3-fold increase in plasma exposure to tacrolimus in a renal transplant patient (CYP3A5 non-expresser) upon initiation of Escordi Cor for the treatment of post-transplant hypertension resulting in reduction of tacrolimus dose has been reported. Irrespective of the CYP3A5 genotype status, the possibility of an interaction cannot be excluded with these drugs.
Pediatric Patients
Sixty-two hypertensive patients aged 6 to 17 years received doses of Escordi Cor between 1.25 mg and 20 mg. Weight-adjusted clearance and volume of distribution were similar to values in adults.
References
- NCIt. "Amlodipine: NCI Thesaurus (NCIt) provides reference terminology for many systems. It covers vocabulary for clinical care, translational and basic research, and public information and administrative activities.". https://ncit.nci.nih.gov/ncitbrowser... (accessed September 17, 2018).
- EPA DSStox. "Amlodipine: DSSTox provides a high quality public chemistry resource for supporting improved predictive toxicology.". https://comptox.epa.gov/dashboard/ds... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Escordi Cor are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Escordi Cor. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported administration
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
